Plain-English translation of NCT06858319 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a follow-up study for adults with IgA nephropathy (a kidney disease where the immune system damages the kidneys) who have already completed an earlier clinical trial. Participants will continue receiving , the investigational medication being tested, to see how safe it is and how well patients tolerate it over a longer period of time.
While earlier studies tested whether this medication works, this longer-term study is designed to make sure the medication remains safe and manageable when patients take it for months or years. This information helps doctors understand whether this treatment can be used safely in real-world practice.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive the study medication () by injection under the skin once every two weeks at 600 mg. You will attend multiple visits at a research center where doctors will monitor your kidney function, check for side effects, and answer any questions you have. The study is open-label, meaning both you and your doctor will know you are receiving the medication, and you will continue until your doctor decides the treatment is no longer beneficial or you choose to stop.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
United States